晚期非小细胞肺癌患者免疫细胞变化与中医证型的相关性研究
|
摘要
目的:探讨晚期非小细胞肺癌(NSCLC)患者T淋巴细胞亚群及NK细胞亚群的变化与中医证型的相关性,为该病中医证型的客观化及指导中医临床治疗提供可参考的依据。方法:采用流式细胞术(FCM),检测60例各中医证型(气虚痰湿型、阴虚热毒型、气阴两虚型、气血瘀滞型)的晚期非小细胞肺癌患者外周血T淋巴细胞亚群及NK细胞亚群。结果:各中医证型组之间CD3+T淋巴细胞比较无统计学意义;CD4+T淋巴细胞以气虚痰湿型为最高,与阴虚热毒型、气阴两虚型及气血瘀滞型比较有统计学意义(P<0.05),CD4+ T淋巴细胞以气阴两虚型为最低;CD8+T淋巴细胞以气阴两虚型最高,各型之间相比较无统计学意义(P﹥0.05);CD4+/CD8+以气阴两虚型为最低,与气虚痰湿型比较有统计学意义(P<0.05),气血瘀滞型CD4+/CD8+与气虚痰湿型比较有统计学意义(P<0.05),CD4+/CD8+以气虚痰湿型为最高。气虚痰湿型患者NK细胞水平最低,阴虚热毒型NK细胞水平最高,各中医证型组间比较无统计学意义(P﹥0.05)。结论:晚期非小细胞肺癌患者免疫细胞与中医证型具有一定的相关性,其中气虚痰湿型的免疫功能最好,气阴两虚型最差,因此监测各中医证型非小细胞肺癌患者免疫细胞的变化有助于推断中医证型间变化规律,指导中医临床治疗。
Objective: to analyse the changes of peripheral blood cell immune function including T lymphocyte subsets and NK cells in advanced Non-small cell lung cancer patients and its correlation with Traditional Chinese medicine syndrome,offer the reference for Traditional Chinese medicine syndrome and instruct Clinical Traditional Chinese medicine therapy. Methods: T lymphocyte subsets and NK cells in 60 patients of the different Traditional Chinese medicine syndrome groups(Qixutanshi、Yinxuredu、Qiyinliangxu、Qixueyuzhi)with Non-small cell lung cancer were measured with flow cytometry(FCM). Results: The levels of CD3+T cell in those patients with Traditional Chinese medicine syndromes were no significant difference,while the level of CD4+ T cell in those patients with Qixutanshi syndrome was the highest and there was significantly difference in comparison with Yinxuredu,Qiyinliangxu,Qixueyuzhi syndromes (P<0.05),the level of CD4+ T cell in those patients with Qiyinliangxu syndrome was the lowest , the level of CD8+ T cell in those patients with Qixutanshi syndrome was the highest,The levels of CD8+T cell in those patients with Traditional Chinese medicine syndromes were no significant difference(P>0.05); The helper/suppressor radio (CD4+/CD8+) in those patients with Qiyinliangxu syndrome was the lowest and the highest in those patients with Qixutanshi syndrome and there was significantly difference in comparison with Qixutanshi syndrome(P<0.05); The helper/suppressor radio (CD4+/CD8+) in those patients with Qixueyuzhi syndrome was significant difference in comparison with Qixutanshi syndrome(P<0.05);The number of NK cell was the lowest in those patients with Qixutanshi syndrome and the highest in those patients with Yinxuredu syndrome,But the NK cells of the different Traditional Chinese medicine syndrome groups were no statistical significance(P>0.05). Conclusion: The peripheral blood immune cells in advanced Non-small cell lung cancer patients had definite relationship with Traditional Chinese medicine syndromes.The immune function of Qixutanshi syndrome patients was the best,While Qinyinliangxu was the worst..It is useful for deducing discipline of Traditional Chinese medicine syndromes and inducting clinical Traditional Chinese medicine remedy of Non-small cell lung cancer patients to measure the changes of T lymphocyte subsets and NK cells.
Objective: to analyse the changes of peripheral blood cell immune function including T lymphocyte subsets and NK cells in advanced Non-small cell lung cancer patients and its correlation with Traditional Chinese medicine syndrome,offer the reference for Traditional Chinese medicine syndrome and instruct Clinical Traditional Chinese medicine therapy. Methods: T lymphocyte subsets and NK cells in 60 patients of the different Traditional Chinese medicine syndrome groups(Qixutanshi、Yinxuredu、Qiyinliangxu、Qixueyuzhi)with Non-small cell lung cancer were measured with flow cytometry(FCM). Results: The levels of CD3+T cell in those patients with Traditional Chinese medicine syndromes were no significant difference,while the level of CD4+ T cell in those patients with Qixutanshi syndrome was the highest and there was significantly difference in comparison with Yinxuredu,Qiyinliangxu,Qixueyuzhi syndromes (P<0.05),the level of CD4+ T cell in those patients with Qiyinliangxu syndrome was the lowest , the level of CD8+ T cell in those patients with Qixutanshi syndrome was the highest,The levels of CD8+T cell in those patients with Traditional Chinese medicine syndromes were no significant difference(P>0.05); The helper/suppressor radio (CD4+/CD8+) in those patients with Qiyinliangxu syndrome was the lowest and the highest in those patients with Qixutanshi syndrome and there was significantly difference in comparison with Qixutanshi syndrome(P<0.05); The helper/suppressor radio (CD4+/CD8+) in those patients with Qixueyuzhi syndrome was significant difference in comparison with Qixutanshi syndrome(P<0.05);The number of NK cell was the lowest in those patients with Qixutanshi syndrome and the highest in those patients with Yinxuredu syndrome,But the NK cells of the different Traditional Chinese medicine syndrome groups were no statistical significance(P>0.05). Conclusion: The peripheral blood immune cells in advanced Non-small cell lung cancer patients had definite relationship with Traditional Chinese medicine syndromes.The immune function of Qixutanshi syndrome patients was the best,While Qinyinliangxu was the worst..It is useful for deducing discipline of Traditional Chinese medicine syndromes and inducting clinical Traditional Chinese medicine remedy of Non-small cell lung cancer patients to measure the changes of T lymphocyte subsets and NK cells.
引文
[1]全香兰.肺癌患者危险因素的分析[J].中国现代医药杂志,2007,9(12):129
[2]郭建新,邵国安,孙祝生.乌鲁木齐市某院1407例恶性肿瘤病例统计分析[J].中国医院统计,2007.12,14(4):338
[3]阮萍,宋向芹,于俊风等.1312例癌症患者统计分析[J].中国医院统计,2004,11(1): 90-91
[4]刘嘉湘.现代中医药应用与研究大系.肿瘤科[M].上海:上海中医药大学出版社, 1996.130.
[5]洪广祥.原发性支气管肺癌中医药治疗的探讨[J].江西中医药,1995,26(6): 2
[6]陈玉琨.除痰祛瘀法治疗肺癌的理论认识和临床应用[J].新中医,1993,(1): 10
[7]王银山.蔡光先教授论肺癌病因病机治则及用药特色[J].中医药学刊,2003, 21(1):27
[8]杨海江,陈家鑫.从脾胃论治肺癌的机理探讨[J].Journal of Shaanxi College of Traditional Chinese Medicine,2007,l(30):2
[9]张霆.从伏气学说探讨肺癌之病因病机[J].中医研究,2007,20(3):5-6
[10]郑筱萸主编.《中药新药临床研究指导原则》,中国医药科技出版社,2002
[11]中国抗癌协会编.《新编中国常见恶性肿瘤诊治规范》原发性支气管肺癌分册,1997
[12] F.L.格林尼,D.L.佩基,I.D.弗莱明等主编,《AJCC癌症分期手册》,第6版.辽宁科学技术出版社,2005
[13]颜虹主编.卫生统计学[M].北京:人民卫生出版社,2005:258
[14]李泽庚,张杰根.肺气虚证的神经内分泌免疫网络研究现状及探讨[J],中医药学刊. 2005,23(9): 1602-1604
[15]郑红刚,花宝金.朴炳奎辨证治疗肺癌的学术思想[J].北京中医,2007.5,26(5):273
[16]王芬,胡凯文,陈文强等.中晚期肺癌的中医聚类分型[J].中国中医药信息杂志, 2006.10,13(10): 28-29
[17]刘嘉湘.辨证治疗原发性肺癌310例疗效分析[J].上海中医药志,1985(12):3
[18]顾梦飚.480例原发性肺癌中医证型与国际TNM分期相关分[J].上海中医药杂志,1994(1): 1
[19]李慧芬,申维玺,刘玉梅等.气虚证与肺癌临床病理特征的关系研究[J].肿瘤基础与临床,2007 20(1):62
[20]王笑民.晚期非小细胞肺癌患者气虚血瘀证的研究[J].中国中医结合杂志, 1994,14(12):724
[21]陈锐深,张佗.肺癌578例辨证论治[J].亚洲医药,1997(5):2
[22]张淑香.晚期非小细胞肺癌的预后因子分析[J].现代中西医结合杂志.2006. 3, 15(6):705
[23]刘嘉湘.现代中医药应用与研究大系(第l4卷)[M].上海:上海中医药大学出版社,1996:130
[24]刘嘉湘,施志明,徐振晔.滋阴生津益气温阳法治疗晚期原发性肺癌的临床研究[J].中医杂志, 1995, 36(3): 155
[25]马纯正,牛喜伟.中医辨证治疗晚期非小细胞肺癌62例[J].中医杂志, 2003, 44(8): 6
[26]李峥嵘.中医药辨证分型治疗肺癌125例[J].河南中医学院学报,2004, 19(3): 53
[27]冯月娟,张建芳,张国良.112例肺癌中医证型,舌象与病理分型关系探讨[J].中国中医急症,2004,13(7):446-447
[28]陈四清.肺癌证治六法[J].陕西中医,2004,24(4):345-347
[29]王维.原发性支气管肺癌的辨证论治[J].中华实用中西医杂志,2005,14(4):399-401
[30]张淑香.晚期非小细胞肺癌的证候研究,中医药学刊,2006,24(4):678-679
[31]陈四清.原发性支气管肺癌辨证分型探讨[J].新中医,2034(11):6-8
[32]裘宇容,曾方要,杨春莉.流式细胞仪对4种癌症患者T淋巴细胞亚群的检测〔J〕.第一军医大学学报,1998,18(2): 151
[33]巴德年,主编.当代免疫学技术与应用.北京:北京医科大学中国协和医科大学联合出版社, 1998.11
[34]黄辉,俞红,林云璐. CD4+细胞的抗瘤作用.国外医学.免疫学分册, 2000, 23 (1): 51
[35]张淑香.晚期非小细胞肺癌的预后因子分析[J].现代中西医结合杂志.2006. 3, 15(6):705
[36]沈玉光,许金良,杨宗林等.流式细胞术测肺癌患者外周血T细胞亚群及其与临床病理的关系.实用诊断与治疗杂志.2006 20(2):101-102
[37]张淑香.晚期非小细胞肺癌的预后因子分析[J].现代中西医结合杂志.2006. 3, 15(6):705
[38]张淑香.晚期非小细胞肺癌的预后因子分析[J].现代中西医结合杂志.2006. 3, 15(6):706
[39] oannides CG.Whiteside TL.T cell recognition of human tumors: Implirations for molecular immunotherapy of cancer.Clin Immunol and Immunopathol,1993;66:91
[40] Morton BA,Ramey WG,Paderon H et al.Monoclonal anthibody defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in carly breast cancer,Cancer Res,1986;46
[41]张淑香.晚期非小细胞肺癌的预后因子分析[J].现代中西医结合杂志.2006. 3,15(6):705
[42]张淑香.晚期非小细胞肺癌的预后因子分析[J].现代中西医结合杂志.2006. 3, 15(6):706
[43]陈锐深.肺癌587例辨证论治[J].亚洲医药, 1997, 5: 21.
[44]王亚娟,王爱芬.肺癌患者外周血T淋巴细胞亚群检测的临床研究[J].肿瘤防治杂志,2004.7,11(7):727-728
[45]李进东,许金良,王文光等.肺癌患者外周血T淋巴细胞亚群的变化[J].中国医师进修杂志外科版,2006.11B,29(11):25
[46]李秀义.NK细胞活性改变及化疗对肺癌患者的影响[J].安徽卫生职业技术学院学报,2004,3(3):64-65
[47]沈历宗,吴文溪,华一兵等.大肠癌患者外周血T细胞亚群、NK细胞活性及可溶性白介素2受体检测的临床意义[J].南京医科大学学报, 2000, 20(4): 285-287
[48]陆宏,孔宪涛,仲入前等.CD16+细胞表达与NK活性的关系.中国免疫学杂志, 1997, 13(3):177
[49]李进东,许金良,王文光等.肺癌患者外周血T淋巴细胞亚群的变化[J].中国医师进修杂志外科版,2006,11 B. 29(11):25-26
[50]李柳宁,刘伟胜,徐凯等.中医辨证施治结合化疗对中晚期非小细胞肺癌预后因子的影响[J].中西医结合杂志, 2003, 23(8):575
[51]孙建立.刘嘉湘教授研究肺癌中医诊治规律的思路探讨.上海中医药杂志,2002(9):11
[52]周伟生,杨贤卫,何蓉.中晚期周围型肺癌临床分期病理分型与中医证型相关性研究.中医药学刊,2006,24(8):1436
[53]陈岳青,邹学森,黄秀珍等.非小细胞肺癌患者外周血T淋巴细胞亚群及NK细胞亚群分析及临床意义.实用癌症杂志,2006,21(5):476
[54]刘莉,姚军霞,丁乾等.非小细胞肺癌患者外周血CD4+CD25+调节T细胞的检测及其临床意义.肿瘤,2006,26(2):171
[55]黄作平,邹冰心,刘兴京等.非小细胞肺癌病程中免疫细胞的变化.江苏医药,2007,33(4):412
[56]王亚娟,王爱芬.肺癌患者外周血T淋巴细胞亚群检测的临床研究.肿瘤防治杂志,2004,11(7):726-727
[57]喻光懋,崔健,周伟军等,肺癌术后早期营养支持对机体免疫功能影响.中国肿瘤,2004,13(2):109
[58]张敬川,王红兵,高超等.非小细胞肺癌患者T细胞亚群变化的临床意义[J].徐州医学院学报,2002,22(6):537
[1]王海勇,喻光懋,崔健.鸦胆子油乳注射液联合化疗对晚期肺癌患者免疫功能的影响[J].现代中西医结合杂志,2006,15(5):591
[2]杨祖贻,罗洁.中药对Ⅲ-Ⅳ期肺癌患者化疗骨髓抑制及生活质量的影响[J].四川中医,2005,23(2):10-12
[3]施伶俐,周红,童稳圃,闵屹华.针药复合麻醉对肺癌手术患者γ干扰素免疫调节活性的影响[J].上海针灸杂志,2005,24(3):18-19
[4]董晓辉,董竞成.黄芪注射液增强树突细胞的抗肺癌作用[J].中国实验方剂学杂志,2005,11(1):25-28
[5]杨泽江,邱英和,邓朝明.加减泻白散联合放、化疗治疗中晚期非小细胞肺癌32例临床观察[J].四川中医,2005 ,23(1):37
[6]郑婉珍,丁纪元.百士欣胶囊对非小细胞肺癌化疗减毒作用的研究[J].现代中西医结合杂志,2005,14(4):437-438
[7]刘剑,张爱国,焦鲁青.复方苦参注射液联合化疗治疗肺癌临床观察[J].中国现代医学杂志,2006,16(1)
[8]计磊,顾人东,李西启. BCL-2基因产物在晚期非小细胞肺癌中药治疗前后的表达[J].实用中西医结合杂志,1997,10(17):1683
[9]刘春英,井欢,蔡硕,等.肺癌平药物血清对A549人肺癌细胞增殖的影响[J].中国中医基础医学杂志,2005,11(2):132-133
[10]潘云华,潘琦.复方三根制剂对T739小鼠肺癌转移的实验研究[J].浙江中西医结合杂志,2005,15(2):77-78
[11]王哲,刘春英,郝宏党,等.益气活血解毒方诱导小鼠肺癌细胞凋亡的研究[J].中国中医药信息杂志,2005,12(2):43
[12]崔建东,胡义德..姜黄素与顺铂联合对人肺腺癌A549细胞增殖抑制作用的体外研究[J].四川医学,2006,27(1):3
[13]王长秀,马润娣,于立坚.土贝母皂苷对人高转移巨细胞肺癌PGCL3细胞侵袭行为的影响[J].ChinJClinPharmacolTher,2006,11(1):44
[14]沈晓鸣,黄炜,黄济群.姜黄素对高转移人肺癌细胞亚系生物学行为的影响[J].广东医学院学报,2001,19(1):1-3)
[15]毛海婷,张玲,王芸等.淫羊藿甙抗癌作用机制的实验研究[J].中药材,2000,23(9): 554-556
[16]朱世杰,贾立群,李佩文.艾迪注射液抑制肿瘤新生血管形成的实验研究[C].贵阳:全国中西医治疗肿瘤高级论坛论文汇编,2002.106.
[17]林洪生,李树奇,朴炳奎等.三参冲剂对肺癌转移中内皮细胞及黏附因子的影响[J].中国肿瘤,1999,8(12):574
[18]赵丽红,孙慧莉,徐蔚杰,田建辉.SCD44V6与非小细胞肺癌术后转移及中医分型的临床分析[J].中华现代中西医杂志,2005,3(16):1441-1442
[19]徐荣贵.中医辨证合MVP方案治疗晚期非小细胞肺癌[J].浙江中西医结合杂志,2005,15(7):403
[20]施志明.原发性肺癌中医辨证分型与西医分期及细胞类型的关系[J].中国癌症杂志,1998,4(8):317-318
[21]贾桂娈,褚东宁.肺癌X线征象和病理分型与中医证型关系的分析[J].浙江中西医结合杂志,2001,11(2):107
[22]米逸颖,胡亚军,周美珍,等.肺癌中医辨证分型与血清硒关系[J].中国中西医结合杂志,1995,15(11):658-660
[23]王芬等.晚期小细胞肺癌中医证候与生存质量关系研究[J].中国中医药信息杂志,2004,11(9):790-791
[2]郭建新,邵国安,孙祝生.乌鲁木齐市某院1407例恶性肿瘤病例统计分析[J].中国医院统计,2007.12,14(4):338
[3]阮萍,宋向芹,于俊风等.1312例癌症患者统计分析[J].中国医院统计,2004,11(1): 90-91
[4]刘嘉湘.现代中医药应用与研究大系.肿瘤科[M].上海:上海中医药大学出版社, 1996.130.
[5]洪广祥.原发性支气管肺癌中医药治疗的探讨[J].江西中医药,1995,26(6): 2
[6]陈玉琨.除痰祛瘀法治疗肺癌的理论认识和临床应用[J].新中医,1993,(1): 10
[7]王银山.蔡光先教授论肺癌病因病机治则及用药特色[J].中医药学刊,2003, 21(1):27
[8]杨海江,陈家鑫.从脾胃论治肺癌的机理探讨[J].Journal of Shaanxi College of Traditional Chinese Medicine,2007,l(30):2
[9]张霆.从伏气学说探讨肺癌之病因病机[J].中医研究,2007,20(3):5-6
[10]郑筱萸主编.《中药新药临床研究指导原则》,中国医药科技出版社,2002
[11]中国抗癌协会编.《新编中国常见恶性肿瘤诊治规范》原发性支气管肺癌分册,1997
[12] F.L.格林尼,D.L.佩基,I.D.弗莱明等主编,《AJCC癌症分期手册》,第6版.辽宁科学技术出版社,2005
[13]颜虹主编.卫生统计学[M].北京:人民卫生出版社,2005:258
[14]李泽庚,张杰根.肺气虚证的神经内分泌免疫网络研究现状及探讨[J],中医药学刊. 2005,23(9): 1602-1604
[15]郑红刚,花宝金.朴炳奎辨证治疗肺癌的学术思想[J].北京中医,2007.5,26(5):273
[16]王芬,胡凯文,陈文强等.中晚期肺癌的中医聚类分型[J].中国中医药信息杂志, 2006.10,13(10): 28-29
[17]刘嘉湘.辨证治疗原发性肺癌310例疗效分析[J].上海中医药志,1985(12):3
[18]顾梦飚.480例原发性肺癌中医证型与国际TNM分期相关分[J].上海中医药杂志,1994(1): 1
[19]李慧芬,申维玺,刘玉梅等.气虚证与肺癌临床病理特征的关系研究[J].肿瘤基础与临床,2007 20(1):62
[20]王笑民.晚期非小细胞肺癌患者气虚血瘀证的研究[J].中国中医结合杂志, 1994,14(12):724
[21]陈锐深,张佗.肺癌578例辨证论治[J].亚洲医药,1997(5):2
[22]张淑香.晚期非小细胞肺癌的预后因子分析[J].现代中西医结合杂志.2006. 3, 15(6):705
[23]刘嘉湘.现代中医药应用与研究大系(第l4卷)[M].上海:上海中医药大学出版社,1996:130
[24]刘嘉湘,施志明,徐振晔.滋阴生津益气温阳法治疗晚期原发性肺癌的临床研究[J].中医杂志, 1995, 36(3): 155
[25]马纯正,牛喜伟.中医辨证治疗晚期非小细胞肺癌62例[J].中医杂志, 2003, 44(8): 6
[26]李峥嵘.中医药辨证分型治疗肺癌125例[J].河南中医学院学报,2004, 19(3): 53
[27]冯月娟,张建芳,张国良.112例肺癌中医证型,舌象与病理分型关系探讨[J].中国中医急症,2004,13(7):446-447
[28]陈四清.肺癌证治六法[J].陕西中医,2004,24(4):345-347
[29]王维.原发性支气管肺癌的辨证论治[J].中华实用中西医杂志,2005,14(4):399-401
[30]张淑香.晚期非小细胞肺癌的证候研究,中医药学刊,2006,24(4):678-679
[31]陈四清.原发性支气管肺癌辨证分型探讨[J].新中医,2034(11):6-8
[32]裘宇容,曾方要,杨春莉.流式细胞仪对4种癌症患者T淋巴细胞亚群的检测〔J〕.第一军医大学学报,1998,18(2): 151
[33]巴德年,主编.当代免疫学技术与应用.北京:北京医科大学中国协和医科大学联合出版社, 1998.11
[34]黄辉,俞红,林云璐. CD4+细胞的抗瘤作用.国外医学.免疫学分册, 2000, 23 (1): 51
[35]张淑香.晚期非小细胞肺癌的预后因子分析[J].现代中西医结合杂志.2006. 3, 15(6):705
[36]沈玉光,许金良,杨宗林等.流式细胞术测肺癌患者外周血T细胞亚群及其与临床病理的关系.实用诊断与治疗杂志.2006 20(2):101-102
[37]张淑香.晚期非小细胞肺癌的预后因子分析[J].现代中西医结合杂志.2006. 3, 15(6):705
[38]张淑香.晚期非小细胞肺癌的预后因子分析[J].现代中西医结合杂志.2006. 3, 15(6):706
[39] oannides CG.Whiteside TL.T cell recognition of human tumors: Implirations for molecular immunotherapy of cancer.Clin Immunol and Immunopathol,1993;66:91
[40] Morton BA,Ramey WG,Paderon H et al.Monoclonal anthibody defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in carly breast cancer,Cancer Res,1986;46
[41]张淑香.晚期非小细胞肺癌的预后因子分析[J].现代中西医结合杂志.2006. 3,15(6):705
[42]张淑香.晚期非小细胞肺癌的预后因子分析[J].现代中西医结合杂志.2006. 3, 15(6):706
[43]陈锐深.肺癌587例辨证论治[J].亚洲医药, 1997, 5: 21.
[44]王亚娟,王爱芬.肺癌患者外周血T淋巴细胞亚群检测的临床研究[J].肿瘤防治杂志,2004.7,11(7):727-728
[45]李进东,许金良,王文光等.肺癌患者外周血T淋巴细胞亚群的变化[J].中国医师进修杂志外科版,2006.11B,29(11):25
[46]李秀义.NK细胞活性改变及化疗对肺癌患者的影响[J].安徽卫生职业技术学院学报,2004,3(3):64-65
[47]沈历宗,吴文溪,华一兵等.大肠癌患者外周血T细胞亚群、NK细胞活性及可溶性白介素2受体检测的临床意义[J].南京医科大学学报, 2000, 20(4): 285-287
[48]陆宏,孔宪涛,仲入前等.CD16+细胞表达与NK活性的关系.中国免疫学杂志, 1997, 13(3):177
[49]李进东,许金良,王文光等.肺癌患者外周血T淋巴细胞亚群的变化[J].中国医师进修杂志外科版,2006,11 B. 29(11):25-26
[50]李柳宁,刘伟胜,徐凯等.中医辨证施治结合化疗对中晚期非小细胞肺癌预后因子的影响[J].中西医结合杂志, 2003, 23(8):575
[51]孙建立.刘嘉湘教授研究肺癌中医诊治规律的思路探讨.上海中医药杂志,2002(9):11
[52]周伟生,杨贤卫,何蓉.中晚期周围型肺癌临床分期病理分型与中医证型相关性研究.中医药学刊,2006,24(8):1436
[53]陈岳青,邹学森,黄秀珍等.非小细胞肺癌患者外周血T淋巴细胞亚群及NK细胞亚群分析及临床意义.实用癌症杂志,2006,21(5):476
[54]刘莉,姚军霞,丁乾等.非小细胞肺癌患者外周血CD4+CD25+调节T细胞的检测及其临床意义.肿瘤,2006,26(2):171
[55]黄作平,邹冰心,刘兴京等.非小细胞肺癌病程中免疫细胞的变化.江苏医药,2007,33(4):412
[56]王亚娟,王爱芬.肺癌患者外周血T淋巴细胞亚群检测的临床研究.肿瘤防治杂志,2004,11(7):726-727
[57]喻光懋,崔健,周伟军等,肺癌术后早期营养支持对机体免疫功能影响.中国肿瘤,2004,13(2):109
[58]张敬川,王红兵,高超等.非小细胞肺癌患者T细胞亚群变化的临床意义[J].徐州医学院学报,2002,22(6):537
[1]王海勇,喻光懋,崔健.鸦胆子油乳注射液联合化疗对晚期肺癌患者免疫功能的影响[J].现代中西医结合杂志,2006,15(5):591
[2]杨祖贻,罗洁.中药对Ⅲ-Ⅳ期肺癌患者化疗骨髓抑制及生活质量的影响[J].四川中医,2005,23(2):10-12
[3]施伶俐,周红,童稳圃,闵屹华.针药复合麻醉对肺癌手术患者γ干扰素免疫调节活性的影响[J].上海针灸杂志,2005,24(3):18-19
[4]董晓辉,董竞成.黄芪注射液增强树突细胞的抗肺癌作用[J].中国实验方剂学杂志,2005,11(1):25-28
[5]杨泽江,邱英和,邓朝明.加减泻白散联合放、化疗治疗中晚期非小细胞肺癌32例临床观察[J].四川中医,2005 ,23(1):37
[6]郑婉珍,丁纪元.百士欣胶囊对非小细胞肺癌化疗减毒作用的研究[J].现代中西医结合杂志,2005,14(4):437-438
[7]刘剑,张爱国,焦鲁青.复方苦参注射液联合化疗治疗肺癌临床观察[J].中国现代医学杂志,2006,16(1)
[8]计磊,顾人东,李西启. BCL-2基因产物在晚期非小细胞肺癌中药治疗前后的表达[J].实用中西医结合杂志,1997,10(17):1683
[9]刘春英,井欢,蔡硕,等.肺癌平药物血清对A549人肺癌细胞增殖的影响[J].中国中医基础医学杂志,2005,11(2):132-133
[10]潘云华,潘琦.复方三根制剂对T739小鼠肺癌转移的实验研究[J].浙江中西医结合杂志,2005,15(2):77-78
[11]王哲,刘春英,郝宏党,等.益气活血解毒方诱导小鼠肺癌细胞凋亡的研究[J].中国中医药信息杂志,2005,12(2):43
[12]崔建东,胡义德..姜黄素与顺铂联合对人肺腺癌A549细胞增殖抑制作用的体外研究[J].四川医学,2006,27(1):3
[13]王长秀,马润娣,于立坚.土贝母皂苷对人高转移巨细胞肺癌PGCL3细胞侵袭行为的影响[J].ChinJClinPharmacolTher,2006,11(1):44
[14]沈晓鸣,黄炜,黄济群.姜黄素对高转移人肺癌细胞亚系生物学行为的影响[J].广东医学院学报,2001,19(1):1-3)
[15]毛海婷,张玲,王芸等.淫羊藿甙抗癌作用机制的实验研究[J].中药材,2000,23(9): 554-556
[16]朱世杰,贾立群,李佩文.艾迪注射液抑制肿瘤新生血管形成的实验研究[C].贵阳:全国中西医治疗肿瘤高级论坛论文汇编,2002.106.
[17]林洪生,李树奇,朴炳奎等.三参冲剂对肺癌转移中内皮细胞及黏附因子的影响[J].中国肿瘤,1999,8(12):574
[18]赵丽红,孙慧莉,徐蔚杰,田建辉.SCD44V6与非小细胞肺癌术后转移及中医分型的临床分析[J].中华现代中西医杂志,2005,3(16):1441-1442
[19]徐荣贵.中医辨证合MVP方案治疗晚期非小细胞肺癌[J].浙江中西医结合杂志,2005,15(7):403
[20]施志明.原发性肺癌中医辨证分型与西医分期及细胞类型的关系[J].中国癌症杂志,1998,4(8):317-318
[21]贾桂娈,褚东宁.肺癌X线征象和病理分型与中医证型关系的分析[J].浙江中西医结合杂志,2001,11(2):107
[22]米逸颖,胡亚军,周美珍,等.肺癌中医辨证分型与血清硒关系[J].中国中西医结合杂志,1995,15(11):658-660
[23]王芬等.晚期小细胞肺癌中医证候与生存质量关系研究[J].中国中医药信息杂志,2004,11(9):790-791